Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: Circulation. 2016 Mar 15;133(11):1115–1124. doi: 10.1161/CIRCULATIONAHA.115.018622

Figure 3.

Figure 3

Kaplan-Meier curves from the PARADIGM-HF trial for the primary composite endpoint of cardiovascular death or first hospitalization for heart failure (A), death from cardiovascular causes (B), first hospitalization for heart failure (C), and death from any cause (D). LCZ696 is valsartan/sacubitril. Reproduced with permission from the publisher. Copyright © 2014, Massachusetts Medical Society. All rights reserved.